author
contribut
equal
work
transplant
recipi
respiratori
viral
infect
rvi
associ
high
rate
morbid
mortal
although
recent
report
underlin
increas
import
rvi
solid
organ
transplant
sot
recipi
littl
known
incid
earli
transplant
immunosuppress
regimen
impair
sot
recipi
immun
system
disabl
protect
infect
fact
viral
pneumonia
repres
caus
death
among
sot
recipi
character
incid
rvi
sot
recipi
first
month
posttransplant
use
new
molecular
techniqu
sinc
viru
es
associ
one
specif
syndrom
identif
rv
may
use
appropri
infect
control
surveil
practic
perform
prospect
studi
enrol
ninetyeight
sot
patient
februari
februari
rvi
test
multiplexpcr
mpcr
detect
kit
seegen
inc
detect
rv
human
metapneumoviru
adenoviru
coronaviru
parainfluenza
rhinoviru
ab
respiratori
syncyti
ab
influenza
ab
first
month
sot
incid
rvi
relev
tabl
patient
symptomat
rest
patient
patient
asymptomat
infect
coinfect
influenza
viru
major
caus
coinfect
four
asymptomat
patient
later
develop
symptom
day
post
test
thu
overal
incid
symptom
associ
rvi
within
first
month
transplant
higher
compar
studi
probabl
due
assay
use
found
high
rate
rvi
asymptomat
patient
previous
report
probabl
studi
describ
rvi
symptomat
episod
primari
overal
etiolog
rvi
influenza
februarymarch
adenoviru
octob
coronaviru
march
marchapril
result
conson
studi
show
highest
rate
infect
februari
march
major
case
associ
influenza
infect
nearli
half
symptomat
patient
overcom
infect
absenc
sever
symptom
requir
antivir
administr
incid
rvi
associ
type
graft
renal
transplant
liver
recipi
heart
recipi
viral
infect
significantli
lower
patient
receiv
tripl
immunosuppress
therapi
compar
quadrupl
immunosuppress
therapi
pvalu
wilcoxon
test
tabl
addit
found
higher
rate
rvi
patient
high
risk
cmv
infect
cmv
seroneg
recipi
receiv
graft
seroposit
donor
pvalu
wilcoxon
test
addit
mpcr
two
addit
method
use
diagnosi
rvi
viral
cultur
follow
mpcr
detect
human
metapneumoviru
adenoviru
coronaviru
parainfluenza
rhinoviru
ab
respiratori
syncyti
ab
influenza
ab
immunofluoresc
ifa
biotrinrv
panel
biotrinintern
ltd
alon
detect
adenoviru
influenza
ab
parainfluenza
respiratori
syncyti
viru
fig
sampl
gave
ident
result
use
three
assay
demonstr
mpcr
detect
respiratori
viru
cultur
ifa
agreement
previou
result
import
consid
rvi
especi
influenza
viru
immunosuppress
patient
sinc
earli
antivir
therapi
symptomat
case
associ
improv
outcom
given
high
rate
rvi
measur
avoid
nosocomi
transmiss
rigor
infect
control
measur
patient
isol
avoid
contact
symptomat
caregiv
thu
may
necessari
increas
vaccin
rate
among
sot
candid
also
close
contact
order
confer
indirect
protect
nonrespond
vaccin
instituto
de
salud
carlo
iiifi
plan
nacion
de
desarrollo
e
author
declar
conflict
interest
studi
approv
virgen
del
univers
hospit
ethic
committe
